Antisense oligonucleotides are synthetic sequences of nucleic acid, which reduce appearance of m-RNA. Antisense oligonucleotide is used as a therapeutic agent to treat neurodegenerative disorders. It to prevent disease development by blocking metabolic pathway of a particular protein. This is done by binding the antisense oligonucleotide to the m-RNA from which protein is normally synthesized. Antisense oligonucleotide plays a major role in modern healthcare, as it acts on the messenger RNA level before the protein is formed to inhibit expression of certain diseases-causing genes. The market player increasing their focus on developing CNS associated new drug which is used to treat various types of disorders such as hereditary transthyretin amyloidosis (hATTR), spinal muscular atrophy and Huntington’s disease
COVID-19 Scenario Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
As the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the “World Health Organization” announcing it a public health emergency. The global impacts of the COVID-19 pandemic are already starting to be felt, and will significantly affect the CNS specific antisense oligonucleotide market in 2020. COVID-19 can affect the global economy in three main ways by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Globally, North America holds the largest market share and dominate overall CNS specific antisense oligonucleotide market. This attributed to the factors such as increasing government initiative for antisense drugs, increasing incidence of Alzheimer disease, presence of major R&D, presence of major market player, rising demand for antisense drug. However Asia-Pacific, anticipated to expand CNS specific antisense oligonucleotide market growth rate. This is due to the increasing acceptance of antisense drug, rising R&D activities, increasing investment in R&D, rising neurodegenerative disorder and growing geriatric population.
According to U.S. Food and Drug Administration’s, in 2018, around 15,000 people, affected with angelman syndrome. It is a rare neurogenetic disorder across the globe. According to “National Center for Biotechnology Information (NCBI)”, in 2018, around 5.5 million people suffering from Alzheimer disease in the U.S. and the 24 million affected with this disease across the globe. Alzheimer disease is the most frequent cause of dementia in Western societies.
The factor such as increasing incidence of neurodegenerative disorders, rising geriatric population, large number of product pipeline for treatment of neurodegenerative disorders, increasing the focus of market player on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to reduce CNS associated disorders. Furthermore, Increasing the launch of new products for rare disease related with CNS disorders, rising collaboration between the market players, increasing government initiative for antisense oligonucleotides, etc, are drive the growth CNS specific antisense oligonucleotide market. However, the factor that restrain the growth of CNS specific antisense oligonucleotide market include high cost of treatment and development, stringent government regulation and toxic effects of drug. The opportunities available for this market include increasing government initiative, rising R&D activities, growing the launch of CNS associated drug product.
New Product launch to flourish the market:
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the product utilization. Leading market players have determined how improved accuracy can be influential in many applications. In, 2016, “Sarepta Therapeutics” has received the U.S. Food and Drug Administration (FDA) approval for “Exondys 51”. This drug is used for treatment of rare genetic disorder Duchenne muscular dystrophy.
In 2017, “Ionis” and “Biogen” received “Health Canada” approval for launching new drug such as “Spinraza”. This drug is used to treat spinal muscular atrophy in adults, children, and infants. Spinraza may also be used for purposes not listed in this medication guide.
In 2017, “Ionis Pharmaceuticals, Inc.”, initiated a Phase 1/2 clinical study of IONIS-MAPTRx in patients with
mild Alzheimer's disease.
In 2018, “Ionis Pharmaceuticals, Inc.” has enter into the collaboration with “Roche” to develop new drug product such as “IONIS-FB-LRx”. This drug used for the treatment of complement-mediated diseases.
In 2018, “Ionis Pharmaceuticals” has enter into the collaboration with “Akcea Therapeutics” for developing new drug such as “Inotersen”. They received U.S.FDA approval for launching Intosen. This is used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hATTR. Inotersen can help reduce symptoms such as pain, numbness, tingling, abnormal heartbeats, diarrhea, constipation, weakness, and problems with movement in your arms or legs.
In 2019, “Biogen Inc.,” has launched new drug product such as “LINGO-1”. This is a CNS-specific single transmembrane protein expressed in neurons and in oligodendrocytes but absent in astrocytes. In neurons, it functions as an essential coreceptor of the Nogo receptor complex that mediates the inhibition of axonal growth because of regulatory factors present in myelin.
In 2018, “GeneTx Biotherapeutics LLC’s”, has received the U.S. Food and Drug Administration’s (FDA) orphan-drug designation for GTX-101 for the treatment of Angelman syndrome.
Key benefits of the report:
- This study presents the analytical depiction of the global CNS specific antisense oligonucleotide market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global CNS specific antisense oligonucleotide market share.
- The current market is quantitatively analyzed to highlight the global CNS specific antisense oligonucleotide market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global CNS specific antisense oligonucleotide market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the CNS Specific Antisense Oligonucleotide Market research report:
- Who are the leading market players active in CNS specific antisense oligonucleotide market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
CNS Specific Antisense Oligonucleotide Market Report Highlights
| Aspects | Details |
 By Indication |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Alnylam Pharmaceutical Inc., roQRQR Therapeutic N.V., Ionis Pharmaceutical Inc., Biogen Inc., GlaxoSmithKline Inc., Dynacure, Wave Life Sciences Ltd., Q-STATE BIOSCIENCES, INC., Stroke Therapeutic Inc., Roche, Sarepta Therapeutic, Inc., GeneTx Biotherapeutics LLC’s |
Loading Table Of Content...
